{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:20:58Z","timestamp":1788618058576,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,24]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Reactive arthritis is an immune-mediated aseptic arthritis resulting from either genitourinary or gastrointestinal tract in a genetically susceptible host. It commonly presents as oligoarthritis of the lower limbs with or without extra-articular features such as urethritis and non-purulent conjunctivitis. Therapies include non steroidal anti inflammatory drugs (NSAIDs), conventional disease modifying anti-rheumatic drugs (DMARDs) and, rarely, biologics in severe cases. We report the successful use of tofacitinib in four cases of reactive arthritis who failed to respond to conventional therapies.<\/jats:p>","DOI":"10.1093\/mrcr\/rxab029","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T15:20:39Z","timestamp":1642087239000},"page":"167-170","source":"Crossref","is-referenced-by-count":9,"title":["Successful use of tofacitinib in reactive arthritis refractory to conventional therapies \u2013 a case series"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-8303","authenticated-orcid":false,"given":"Debashis","family":"Maikap","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University , Bhubaneswar, Odisha 751024, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanta","family":"Padhan","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University , Bhubaneswar, Odisha 751024, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"2022062410203366700_R1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.autrev.2014.01.005","article-title":"Diagnosis and classification of reactive arthritis","volume":"13","author":"Selmi","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2022062410203366700_R2","first-page":"1","article-title":"Reactive arthritis: update","volume":"26","author":"Bentaleb","year":"2020","journal-title":"Curr Clin Microbiol Rep"},{"key":"2022062410203366700_R3","first-page":"499","article-title":"Reactive arthritis (Reiter\u2019s syndrome)","volume":"60","author":"Barth","year":"1999","journal-title":"Am Fam Physician"},{"key":"2022062410203366700_R4","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20191927","article-title":"Treatment of reactive arthritis with biological agents: a review","volume":"40","author":"Zeng","year":"2020","journal-title":"Biosci Rep"},{"key":"2022062410203366700_R5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10067-018-4022-5","article-title":"Reactive arthritis: update 2018","volume":"37","author":"Garc\u00eda-Kutzbach","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2022062410203366700_R6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0001-7310(09)73372-1","article-title":"Progress in understanding the immunopathogenesis of psoriasis","volume":"100","author":"Mak","year":"2009","journal-title":"Actas Dermosifiliogr"},{"key":"2022062410203366700_R7","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022062410203366700_R8","first-page":"844","article-title":"Reiter\u2019s syndrome: evaluation of preliminary criteria for definite disease: arthritis","volume":"24","author":"Wikens","year":"1981","journal-title":"Rheum"},{"key":"2022062410203366700_R9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rdc.2009.03.010","article-title":"Reactive arthritis: clinical aspects and medical management","volume":"35","author":"Carter","year":"2009","journal-title":"Rheumatic Dis Clinics"},{"key":"2022062410203366700_R10","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.revmed.2010.02.011","article-title":"Arthrite r\u00e9actionnelle dans les suites d\u2019une infection urinaire \u00e0 Escherichia coli [Reactive arthritis due to Escherichia coli urinary tract infection]","volume":"32","author":"Renou","year":"2011","journal-title":"La Revue de m\u00e9decine interne"},{"key":"2022062410203366700_R11","first-page":"201","volume-title":"Reactive Arthritis. Advances in Experimental Medicine and Biology, 455","author":"Keat","year":"1999"},{"key":"2022062410203366700_R12","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3899\/jrheum.080395","article-title":"Influence of HLA-B* 5703 and HLA-B* 1403 on susceptibility to spondyloarthropathies in the Zambian population","volume":"35","author":"Diaz-Pena","year":"2008","journal-title":"J Rheumatol"},{"key":"2022062410203366700_R13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/rheumatology\/key070","article-title":"The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis","volume":"58","author":"Veale","year":"2019","journal-title":"Rheumatology"},{"key":"2022062410203366700_R14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10067-010-1646-5","article-title":"Th-17 associated cytokines in patients with reactive arthritis\/undifferentiated spondyloarthropathy","volume":"30","author":"Singh","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2022062410203366700_R15","doi-asserted-by":"crossref","DOI":"10.4103\/ijdvl.IJDVL_519_18","article-title":"A retrospective case series of 12 patients with chronic reactive arthritis with emphasis on treatment outcome with biologics","volume":"87","author":"Gupta","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2022062410203366700_R16","first-page":"407","article-title":"Infliximab in the treatment of an HIV positive patient with Reiter\u2019s syndrome","volume":"30","author":"Gaylis","year":"2003","journal-title":"J Rheumatol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxab029\/42594886\/rxab029.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/2\/167\/44245095\/rxab029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/2\/167\/44245095\/rxab029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T10:20:48Z","timestamp":1656066048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/6\/2\/167\/6506321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1,13]]},"published-print":{"date-parts":[[2022,6,24]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxab029","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,1,13]]}}}